secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062034
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus reports Q3 net loss $14.8M; positive Phase 1 data for DNTH103, cash $189.9M
--------------------------------------------------------------------------------

- Net loss of $14.8M ($3.78 per share); R&D expenses $8.0M, G&A $8.7M including $4.0M severance.
- Cash, equivalents, and investments $189.9M at Sept. 30, 2023; runway into Q2 2026.
- Phase 1 data: ~60-day half-life, potent classical complement inhibition, no serious adverse events.
- Plan to start Phase 2 trials: gMG in Q1 2024, followed by MMN (1H24) and CIDP (2H24).
- Completed merger with Magenta Therapeutics and $72M private placement led by Fidelity and others.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/0000950170-23-062034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/dnth-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer